Terms: = Lung cancer AND CEP17 AND Treatment
6 results:
1. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract] [Full Text] [Related]
2. Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report.
Liu X; Cao Y; Li Y; Duan X
Ann Palliat Med; 2020 Mar; 9(2):483-487. PubMed ID: 32075402
[TBL] [Abstract] [Full Text] [Related]
3. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract] [Full Text] [Related]
4. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Olaussen KA; Postel-Vinay S
Ann Oncol; 2016 Nov; 27(11):2004-2016. PubMed ID: 27502726
[TBL] [Abstract] [Full Text] [Related]
5. cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract] [Full Text] [Related]
6. HER family receptor and ligand status in thymic carcinoma.
Weissferdt A; Lin H; Woods D; Tang X; Fujimoto J; Wistuba II; Moran CA
Lung Cancer; 2012 Sep; 77(3):515-21. PubMed ID: 22726920
[TBL] [Abstract] [Full Text] [Related]
